相关实验视频

Updated: Jun 25, 2025

Vessel-Sparing Microsurgical Longitudinal Intussusception Vasoepididymostomy to Treat Epididymal Obstructive Azoospermia

Vessel-Sparing Microsurgical Longitudinal Intussusception Vasoepididymostomy to Treat Epididymal Obstructive Azoospermia

Published on: May 27, 2022

在非阻塞性亚精子症男性中接受医学治疗的资格-来自多中心横截面研究的研究结果

Edoardo Pozzi^1,2,3, Greeshma Venigalla¹, Adele Raymo¹

¹Desai Sethi Urology Institute, Miller School of Medicine, University of Miami, Miami, Florida, USA.

|May 28, 2024

概括

这项研究发现,大约30%的非阻塞性精子症 (NOA) 的男性可能受益于克洛米芬酸盐 (CC) 和人类胆性腺激素 (hCG) 等激素疗法,其中37%有资格接受芳酶抑制剂 (AIs). 只有少数NOA患者在手术前接受医疗治疗的候选人.

科学领域:

内分泌学在内分泌学.
生殖医学生殖医学
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

缺乏准确的流行病学数据关于非阻断性亚精子症 (NOA) 患者符合激素优化治疗的条件.
对于NOA患者的药物治疗的治疗前标准需要进一步调查.

研究的目的:

确定符合荷尔蒙优化治疗标准的NOA男性比例.
在手术生殖 (SR) 程序之前,鉴定NOA患者有资格接受克洛米芬酸盐 (CC) /人类胆性淋巴激素 (hCG) 或芳香酶抑制剂 (AI).

主要方法:

一项多中心的横截面研究分析了来自美国,巴西和意大利1644名NOA患者的数据.
评估了荷尔蒙水平 (,LH,雌激素) 和遗传测试 (型,Y微切除).
符合CC/hCG (低T,低LH) 和AI (低T/E2比率) 的资格根据既定标准确定.

主要成果:

28%的NOA患者有资格接受CC和/或hCG治疗.
37%的NOA患者有资格接受芳香酶抑制剂 (AI) 治疗.
17.7%的NOA患者满足了CC/hCG和AI治疗的标准.

结论:

显著比例的NOA男性是荷尔蒙优化治疗的潜在候选人.
大约30%的NOA患者可能从CC/hCG中受益,37%从AI中受益,17%从两者中受益.
在手术生殖手术之前,可以考虑对NOA患者的一个子集进行医学治疗.

关键词:

流行病学流行病学男人不孕不育的原因医学疗法医学疗法医学疗法非阻塞性阿佐精子症.

更多相关视频

Clinical Application of 24 G Cannula Needle and 3-0 Polypropylene Suture in Vas Deferens Exploration

Clinical Application of 24 G Cannula Needle and 3-0 Polypropylene Suture in Vas Deferens Exploration

Published on: February 10, 2023

Mouse Round Spermatid Injection

Mouse Round Spermatid Injection

Published on: January 26, 2024

相关概念视频

Infertility in Males

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....

Spermatogenesis

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...